A Nationwide Screen of Carbapenem-Resistant Klebsiella pneumoniae Reveals an Isolate with Enhanced Virulence and Clinically Undetected Colistin Heteroresistance

The convergence of hypervirulence and multidrug resistance in is a significant concern. Here, we report the first screen for hypermucoviscosity, a trait associated with increased virulence, using a U.S. surveillance collection of carbapenem-resistant (CR) isolates. We identified one hypermucoviscous...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2019-05, Vol.63 (5)
Main Authors: Wozniak, Jessie E, Band, Victor I, Conley, Andrew B, Rishishwar, Lavanya, Burd, Eileen M, Satola, Sarah W, Hardy, Dwight J, Tsay, Rebecca, Farley, Monica M, Jacob, Jesse T, Dumyati, Ghinwa, Jordan, I King, Weiss, David S
Format: Article
Language:English
Subjects:
Carbapenem-Resistant Enterobacteriaceae
Carbapenem-Resistant Enterobacteriaceae - drug effects
Carbapenem-Resistant Enterobacteriaceae - genetics
Carbapenems
Carbapenems - pharmacology
Colistin
Colistin - pharmacology
Drug Resistance, Bacterial - genetics
Epidemiology and Surveillance
Genotype
Klebsiella pneumoniae - drug effects
Klebsiella pneumoniae - genetics
Microbial Sensitivity Tests
Virulence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The convergence of hypervirulence and multidrug resistance in is a significant concern. Here, we report the first screen for hypermucoviscosity, a trait associated with increased virulence, using a U.S. surveillance collection of carbapenem-resistant (CR) isolates. We identified one hypermucoviscous isolate, which carried a gene encoding the KPC-3 carbapenemase, among numerous resistance genes. The strain further exhibited colistin heteroresistance undetected by diagnostics. This convergence of diverse resistance mechanisms and increased virulence underscores the need for enhanced surveillance.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00107-19